tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

New Report Shows Plandaí Biotechnology’s Diabetes Research More Important Than Ever

New Report Shows Plandaí Biotechnology’s Diabetes Research More Important Than Ever

Written by ι Stock Market Media Group Staff — November 19, 2013

Late last week the International Diabetes Federation (IDF) released a report filled with some staggering statistics in the fight against diabetes.  Plandaí Biotechnology, Inc. (OTCQB: PLPL) feels it is producing products that can make a difference in the fight against the disease, and in light of these new numbers from the IDF, those products will be more welcomed than ever. 

The company’s Phytofare™ Catechin Complex is one of the candidates that Plandaí feels can make a difference in the ongoing battle to control diabetes.  In the IDF’s report it stated that worldwide 382 million people live with diabetes which is up from 285 million just four short years ago.  According to the IDF, there are no signs of slowing as the number of people affected by the disease is expected to climb 55 percent to 592 million by 2035. 

These dismal numbers don’t include the many millions of undiagnosed cases around the world which is equally as troubling.  Annual healthcare spending for diabetes is estimated to be $548 billion by the IDF, and as soon as 2018, the annual market for diabetes drugs and devices alone is projected to reach over $114 billion worldwide. 

Factors such as poor diet, a more sedentary lifestyle, and increases in obesity and life expectancy are some of the reasons for the dramatic rise in newly diagnosed cases.  David Whiting is an epidemiologist and public health specialist with the IDF, and he says, “Year after year, the figures seem to be getting worse. All around the world we are seeing increasing numbers of people developing diabetes.” 

Plandaí feels it can address some of these specific issues head on with its products.  Green tea catechins (specifically EGCG) have been well documented to induce weight loss through a process called “thermogenesis” which essentially increases the metabolic rate allowing more fat to be burned.  There is further evidence to suggest that the method of action is ketosis, similar to what is experience from a high-protein diet such as Atkins, etc.  So, high dosages of green tea catechins will enable the body to burn fat while preserving lean muscle mass.

Unfortunately, the dosage necessary to achieve these results in humans often exceeds desired levels and causes unwanted side effects such as nausea.  Plandaí executives believe that the company’s Phytofare™ catechin product will overcome these issues because lower dosages can be used to generate much higher bioavailability.

Most of the data Plandaí currently possesses with regard to diabetes comes from in-vitro studies and third party clinical trials since its product is simply too new to have generated sufficient comparable in-house animal and human data.  The company is actively involved in multiple clinical trials that should shed greater light on the effectiveness of higher bioavailability.

The question remains, what effect will this product have on diabetes?  Very often, heart disease, high blood pressure, hypertension, and diabetes are by-products of obesity.  Plandaí’s scientists anticipate that the use of Phytofare™ Catechin Complex will result in weight loss and correlative decreases in cholesterol levels, high blood pressure, and blood glucose levels, similar to the results achieved through a high-protein diet.

The company has commissioned a human clinical study with KGK Synergize in Canada to specifically address this matter.  In this study they will be testing not only weight loss, but also performing a full blood and lipid panel to help determine the full range of physiologic changes from Phytofare.